Burning and Scaling Probably Associated with Dupilumab Therapy: A Case Report

CASE REPORT: We present the case of a 51-year-old male who experienced temporary desquamation and recurrent burning sensation in primary skin lesions after the injection of dupilumab. The scaling lasted for 1 week and subsided, while the burning became aggravated with each injection of dupilumab, wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Nana, Wang, Qiuyue, Lei, Min, Li, Zhiyong, Li, Tianhao, Hao, Pingsheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393013/
https://www.ncbi.nlm.nih.gov/pubmed/36000004
http://dx.doi.org/10.2147/CCID.S373997
_version_ 1784771180480167936
author Luo, Nana
Wang, Qiuyue
Lei, Min
Li, Zhiyong
Li, Tianhao
Hao, Pingsheng
author_facet Luo, Nana
Wang, Qiuyue
Lei, Min
Li, Zhiyong
Li, Tianhao
Hao, Pingsheng
author_sort Luo, Nana
collection PubMed
description CASE REPORT: We present the case of a 51-year-old male who experienced temporary desquamation and recurrent burning sensation in primary skin lesions after the injection of dupilumab. The scaling lasted for 1 week and subsided, while the burning became aggravated with each injection of dupilumab, which gradually subsides after 8 weeks, and there was no recurrence since then. CONCLUSION: Dupilumab is an emerging and efficacious biologics medication for AD. The burning sensation and scaling we report may be the adverse events of dupilumab. Rare adverse reactions to biologics deserve the attention of physicians.
format Online
Article
Text
id pubmed-9393013
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-93930132022-08-22 Burning and Scaling Probably Associated with Dupilumab Therapy: A Case Report Luo, Nana Wang, Qiuyue Lei, Min Li, Zhiyong Li, Tianhao Hao, Pingsheng Clin Cosmet Investig Dermatol Case Report CASE REPORT: We present the case of a 51-year-old male who experienced temporary desquamation and recurrent burning sensation in primary skin lesions after the injection of dupilumab. The scaling lasted for 1 week and subsided, while the burning became aggravated with each injection of dupilumab, which gradually subsides after 8 weeks, and there was no recurrence since then. CONCLUSION: Dupilumab is an emerging and efficacious biologics medication for AD. The burning sensation and scaling we report may be the adverse events of dupilumab. Rare adverse reactions to biologics deserve the attention of physicians. Dove 2022-08-17 /pmc/articles/PMC9393013/ /pubmed/36000004 http://dx.doi.org/10.2147/CCID.S373997 Text en © 2022 Luo et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Case Report
Luo, Nana
Wang, Qiuyue
Lei, Min
Li, Zhiyong
Li, Tianhao
Hao, Pingsheng
Burning and Scaling Probably Associated with Dupilumab Therapy: A Case Report
title Burning and Scaling Probably Associated with Dupilumab Therapy: A Case Report
title_full Burning and Scaling Probably Associated with Dupilumab Therapy: A Case Report
title_fullStr Burning and Scaling Probably Associated with Dupilumab Therapy: A Case Report
title_full_unstemmed Burning and Scaling Probably Associated with Dupilumab Therapy: A Case Report
title_short Burning and Scaling Probably Associated with Dupilumab Therapy: A Case Report
title_sort burning and scaling probably associated with dupilumab therapy: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393013/
https://www.ncbi.nlm.nih.gov/pubmed/36000004
http://dx.doi.org/10.2147/CCID.S373997
work_keys_str_mv AT luonana burningandscalingprobablyassociatedwithdupilumabtherapyacasereport
AT wangqiuyue burningandscalingprobablyassociatedwithdupilumabtherapyacasereport
AT leimin burningandscalingprobablyassociatedwithdupilumabtherapyacasereport
AT lizhiyong burningandscalingprobablyassociatedwithdupilumabtherapyacasereport
AT litianhao burningandscalingprobablyassociatedwithdupilumabtherapyacasereport
AT haopingsheng burningandscalingprobablyassociatedwithdupilumabtherapyacasereport

Ejemplares similares